Cargando…
In vivo / in vitro Correlation of Pharmacokinetics of Gentamicin, Vancomycin, Teicoplanin and Doripenem in a Bovine Blood Hemodialysis Model
Background: Elimination of a drug during renal replacement therapy is not only dependent on flow rates, molecular size and protein binding, but is often influenced by difficult to predict drug membrane interactions. In vitro models allow for extensive profiling of drug clearance using a wide array o...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264131/ https://www.ncbi.nlm.nih.gov/pubmed/34248646 http://dx.doi.org/10.3389/fphar.2021.702455 |
_version_ | 1783719484163358720 |
---|---|
author | Vossen, M G Pferschy, S Milacek, C Haidinger, M Karolyi, Mario Vass, Zoltan Burgmann, Heinz Maier-Salamon, Alexandra Wicha, S G Jäger, W Zeitlinger, M Stimpfl, T Wittek, T Thalhammer, F |
author_facet | Vossen, M G Pferschy, S Milacek, C Haidinger, M Karolyi, Mario Vass, Zoltan Burgmann, Heinz Maier-Salamon, Alexandra Wicha, S G Jäger, W Zeitlinger, M Stimpfl, T Wittek, T Thalhammer, F |
author_sort | Vossen, M G |
collection | PubMed |
description | Background: Elimination of a drug during renal replacement therapy is not only dependent on flow rates, molecular size and protein binding, but is often influenced by difficult to predict drug membrane interactions. In vitro models allow for extensive profiling of drug clearance using a wide array of hemofilters and flow rates. We present a bovine blood based in vitro pharmacokinetic model for intermittent renal replacement therapy. Methods: Four different drugs were analyzed: gentamicin, doripenem, vancomicin and teicoplanin. The investigated drug was added to a bovine blood reservoir connected to a hemodialysis circuit. In total seven hemofilter models were analyzed using commonly employed flow rates. Pre-filter, post-filter and dialysate samples were drawn, plasmaseparated and analyzed using turbidimetric assays or HPLC. Protein binding of doripenem and vancomycin was measured in bovine plasma and compared to previously published values for human plasma. Results: Clearance values were heavily impacted by choice of membrane material and surface as well as by dialysis parameters such as blood flow rate. Gentamicin clearance ranged from a minimum of 90.12 ml/min in a Baxter CAHP-170 diacetate hemofilter up to a maximum of 187.90 ml/min in a Fresenius medical company Fx80 polysulfone model (blood flow rate 400 ml/min, dialysate flow rate 800 ml/min). Clearance of Gentamicin vs Vancomicin over the F80s hemofilter model using the same flow rates was 137.62 mL vs 103.25 ml/min. Doripenem clearance with the Fx80 was 141.25 ml/min. Conclusion: Clearance values corresponded very well to previously published data from clinical pharmacokinetic trials. In conjunction with in silico pharmacometric models. This model will allow precise dosing recommendations without the need of large scale clinical trials. |
format | Online Article Text |
id | pubmed-8264131 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82641312021-07-09 In vivo / in vitro Correlation of Pharmacokinetics of Gentamicin, Vancomycin, Teicoplanin and Doripenem in a Bovine Blood Hemodialysis Model Vossen, M G Pferschy, S Milacek, C Haidinger, M Karolyi, Mario Vass, Zoltan Burgmann, Heinz Maier-Salamon, Alexandra Wicha, S G Jäger, W Zeitlinger, M Stimpfl, T Wittek, T Thalhammer, F Front Pharmacol Pharmacology Background: Elimination of a drug during renal replacement therapy is not only dependent on flow rates, molecular size and protein binding, but is often influenced by difficult to predict drug membrane interactions. In vitro models allow for extensive profiling of drug clearance using a wide array of hemofilters and flow rates. We present a bovine blood based in vitro pharmacokinetic model for intermittent renal replacement therapy. Methods: Four different drugs were analyzed: gentamicin, doripenem, vancomicin and teicoplanin. The investigated drug was added to a bovine blood reservoir connected to a hemodialysis circuit. In total seven hemofilter models were analyzed using commonly employed flow rates. Pre-filter, post-filter and dialysate samples were drawn, plasmaseparated and analyzed using turbidimetric assays or HPLC. Protein binding of doripenem and vancomycin was measured in bovine plasma and compared to previously published values for human plasma. Results: Clearance values were heavily impacted by choice of membrane material and surface as well as by dialysis parameters such as blood flow rate. Gentamicin clearance ranged from a minimum of 90.12 ml/min in a Baxter CAHP-170 diacetate hemofilter up to a maximum of 187.90 ml/min in a Fresenius medical company Fx80 polysulfone model (blood flow rate 400 ml/min, dialysate flow rate 800 ml/min). Clearance of Gentamicin vs Vancomicin over the F80s hemofilter model using the same flow rates was 137.62 mL vs 103.25 ml/min. Doripenem clearance with the Fx80 was 141.25 ml/min. Conclusion: Clearance values corresponded very well to previously published data from clinical pharmacokinetic trials. In conjunction with in silico pharmacometric models. This model will allow precise dosing recommendations without the need of large scale clinical trials. Frontiers Media S.A. 2021-06-24 /pmc/articles/PMC8264131/ /pubmed/34248646 http://dx.doi.org/10.3389/fphar.2021.702455 Text en Copyright © 2021 Vossen, Pferschy, Milacek, Haidinger, Karolyi, Vass, Burgmann, Maier-Salamon, Wicha, Jäger, Zeitlinger, Stimpfl, Wittek and Thalhammer. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Vossen, M G Pferschy, S Milacek, C Haidinger, M Karolyi, Mario Vass, Zoltan Burgmann, Heinz Maier-Salamon, Alexandra Wicha, S G Jäger, W Zeitlinger, M Stimpfl, T Wittek, T Thalhammer, F In vivo / in vitro Correlation of Pharmacokinetics of Gentamicin, Vancomycin, Teicoplanin and Doripenem in a Bovine Blood Hemodialysis Model |
title |
In vivo / in vitro Correlation of Pharmacokinetics of Gentamicin, Vancomycin, Teicoplanin and Doripenem in a Bovine Blood Hemodialysis Model |
title_full |
In vivo / in vitro Correlation of Pharmacokinetics of Gentamicin, Vancomycin, Teicoplanin and Doripenem in a Bovine Blood Hemodialysis Model |
title_fullStr |
In vivo / in vitro Correlation of Pharmacokinetics of Gentamicin, Vancomycin, Teicoplanin and Doripenem in a Bovine Blood Hemodialysis Model |
title_full_unstemmed |
In vivo / in vitro Correlation of Pharmacokinetics of Gentamicin, Vancomycin, Teicoplanin and Doripenem in a Bovine Blood Hemodialysis Model |
title_short |
In vivo / in vitro Correlation of Pharmacokinetics of Gentamicin, Vancomycin, Teicoplanin and Doripenem in a Bovine Blood Hemodialysis Model |
title_sort | in vivo / in vitro correlation of pharmacokinetics of gentamicin, vancomycin, teicoplanin and doripenem in a bovine blood hemodialysis model |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264131/ https://www.ncbi.nlm.nih.gov/pubmed/34248646 http://dx.doi.org/10.3389/fphar.2021.702455 |
work_keys_str_mv | AT vossenmg invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel AT pferschys invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel AT milacekc invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel AT haidingerm invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel AT karolyimario invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel AT vasszoltan invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel AT burgmannheinz invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel AT maiersalamonalexandra invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel AT wichasg invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel AT jagerw invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel AT zeitlingerm invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel AT stimpflt invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel AT wittekt invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel AT thalhammerf invivoinvitrocorrelationofpharmacokineticsofgentamicinvancomycinteicoplaninanddoripeneminabovinebloodhemodialysismodel |